Member Info for Wiggly

I'd want to go with ava6k also. It must be extremely frightening to be given a high dose of straight dox.

Incredible RNS and incredible statement from the CEO > 'I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients'

Does the market want to see the funding plan or will it finally let rip today? I think it has to be the latter.

I'd love another bite at 50p. Bring it on.

Back to 50p.

I hope

If Dox was not behaving like Dox, how would one explain the incidence of :

- Alopecia

- Anaemia

- Neutropenia

- Thrombocytopenia

??

@touk

Launch Diagnostics generated £14.17 million of non-COVID-19 related revenue in FY21, with total revenues including COVID-19 related products of £32.75 million. Since FY19, the gross margin in total sales has consistently been in the range 44-50% across all products.

Any increase in COVID related revenue WILL HAVE A POSITIVE IMPACT TO AVACTA

Of course pre|CISION is where its at but it is short sighted to right off potential increase in CORIS revenues associated with Covid.

AS alluded during SD that the vision for the DX div was to build and then sell off to PE for xxxM (eg 80-100m)

If possible, we would be in much stronger position to retain ava6k for longer.

Interesting. We are still in Summer with winter months to come. Could be nice bonus revenue for Avacta

https://www.thejournal.ie/pharmacies-pharmacists-covid-antigen-tests-case-numbers-6148135-Aug2023/

THERE HAS BEEN a surge in the number of antigen tests being sold in pharmacies in recent weeks, pharmacists say, as Covid-19 case numbers continue to rise.

Same old back and forth between the usual suspects, which has been going on for YEARS now...

1. Avacta

Avacta shares have dropped from a record 185p in early February to just 104p today, leaving the junior with a £286 million market cap. While it remains highly capitalised with £27 million on the balance sheet, it’s a very strong potential buyout target.

Even after making multiple purchases of its own — including Coris Bioconcept for £7.4 million recently — the majors are almost certainly watching the FTSE AIM company closely.

Flagship AVA6000 — a novel form of standard chemotherapy Doxorubicin — which is coming towards the end of phase 1A clinical trials, recently reported back on its successful fifth dose escalation. Crucially, the company noted that ‘several patients in cohort 5 and earlier cohorts remain on treatment as their disease has not progressed.’

Further, AVA6000 patients are seeing a ‘marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration,’ with clinicians reportedly unable to tell whether patients are even on the drug. And the next cohort will be treated with 2.7 times the standard dose of Dox.

Having taken on board multiple persons of note, Avacta has also just appointed Consilium Strategic Communications as the company’s investor and media relations advisor.

The GOAT of AIM. I like.

12-18 months is completely fine by me.

I don't know anywhere else to move my money with the same risk reward profile offered here.

Also worth noting that 12-18 months does not consider buy out.

I'll be amazed if Avacta make it to the commercialisation stage. If it's good enough to commercialise it's good enough to be bought out.

When did Avacta begin to state the following?

We develop safe and efficacious drugs and high performance diagnostics, based on our proprietary Affimer® and pre|CISIONᵀᴹ platforms.

Could be fireworks tomorrow

If even higher doses of AVA6000 are tolerated then this may make a significant difference to the outcomes for patients in the upcoming efficacy study.

They will definitely DE as high as possible.

Did they release the biopsy data immediately after each Biopsy ?

They can’t pick and choose when to publish material news it has to be released without delay.

That's not true.

Exactly, AS felt comfortable to sign post 'Efficacy' in the RNS 1 week prior to AGM. He has deliberately drawn attention to the topic, a topic that previously he was reluctant to engage on.

13:00 AVA6000 Review of Public Domain Clinical Data.